Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1986 Jan;77(1):157–164. doi: 10.1172/JCI112270

A myeloma paraprotein with specificity for platelet glycoprotein IIIa in a patient with a fatal bleeding disorder.

G DiMinno, F Coraggio, A M Cerbone, A M Capitanio, C Manzo, M Spina, P Scarpato, G M Dattoli, P L Mattioli, M Mancini
PMCID: PMC423321  PMID: 2935559

Abstract

Impaired platelet aggregation, normal shape change, and agglutination and normal ATP secretion and thromboxane synthesis in response to high concentrations of thrombin or arachidonic acid were found in a patient with multiple myeloma and hemorrhagic tendency. The purified IgG1 kappa or its F(ab1)2 fragments induced similar changes when added in vitro to platelet-rich plasma from normal subjects. In addition, the paraprotein inhibited adhesion to glass microbeads, fibrin clot retraction, and binding of radiolabeled fibrinogen or von Willebrand factor to platelets exposed to thrombin or arachidonic acid without affecting intraplatelet levels of cAMP. The radiolabeled para-protein bound to an average of 35,000 sites on normal platelets but it bound to less than 2,000 sites on the platelets from a patient with Glanzmann's thrombasthenia. Immunoprecipitation studies showed that the platelet antigen identified by the paraprotein was the glycoprotein IIIa. Furthermore, binding of radiolabeled prostaglandin E1 (PGE1) to resting platelets as well as binding of von Willebrand factor to platelets stimulated with ristocetin were entirely normal in the presence of patient's inhibitor. These studies indicate that bleeding occurring in dysproteinemia may be the result of a specific interaction of monoclonal paraproteins with platelets. In addition, our data support the concept that the interaction of fibrinogen and/or von Willebrand factor with the platelet glycoprotein IIb-IIIa complex is essential for effective hemostasis.

Full text

PDF
157

Images in this article

162Image
on p.162
162Image
on p.162

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Beardsley D. S., Spiegel J. E., Jacobs M. M., Handin R. I., Lux S. E., 4th Platelet membrane glycoprotein IIIa contains target antigens that bind anti-platelet antibodies in immune thrombocytopenias. J Clin Invest. 1984 Nov;74(5):1701–1707. doi: 10.1172/JCI111587. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bennett J. S., Hoxie J. A., Leitman S. F., Vilaire G., Cines D. B. Inhibition of fibrinogen binding to stimulated human platelets by a monoclonal antibody. Proc Natl Acad Sci U S A. 1983 May;80(9):2417–2421. doi: 10.1073/pnas.80.9.2417. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bennett J. S., Vilaire G. Exposure of platelet fibrinogen receptors by ADP and epinephrine. J Clin Invest. 1979 Nov;64(5):1393–1401. doi: 10.1172/JCI109597. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Brass L. F., Shattil S. J., Kunicki T. J., Bennett J. S. Effect of calcium on the stability of the platelet membrane glycoprotein IIb-IIIa complex. J Biol Chem. 1985 Jul 5;260(13):7875–7881. [PubMed] [Google Scholar]
  5. Caen J. P., Cronberg S., Levy-Toledano S., Kubisz P., Pinkhas J. P. New data on Glanzmann's thrombasthenia. Proc Soc Exp Biol Med. 1971 Apr;136(4):1082–1086. doi: 10.3181/00379727-136-35432. [DOI] [PubMed] [Google Scholar]
  6. Chediak J., Telfer M. C., Vander Laan B., Maxey B., Cohen I. Cycles of agglutination-disagglutination induced by ristocetin in thrombasthenic platelets. Br J Haematol. 1979 Sep;43(1):113–126. doi: 10.1111/j.1365-2141.1979.tb03726.x. [DOI] [PubMed] [Google Scholar]
  7. Coleman M., Vigliano E. M., Weksler M. E., Nachman R. L. Inhibition of fibrin monomer polymerization by lambda myeloma globulins. Blood. 1972 Feb;39(2):210–223. [PubMed] [Google Scholar]
  8. Coller B. S., Peerschke E. I., Scudder L. E., Sullivan C. A. A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa. J Clin Invest. 1983 Jul;72(1):325–338. doi: 10.1172/JCI110973. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Di Minno G., Cerbone A. M., Mattioli P. L., Turco S., Iovine C., Mancini M. Functionally thrombasthenic state in normal platelets following the administration of ticlopidine. J Clin Invest. 1985 Feb;75(2):328–338. doi: 10.1172/JCI111705. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Di Minno G., Thiagarajan P., Perussia B., Martinez J., Shapiro S., Trinchieri G., Murphy S. Exposure of platelet fibrinogen-binding sites by collagen, arachidonic acid, and ADP: inhibition by a monoclonal antibody to the glycoprotein IIb-IIIa complex. Blood. 1983 Jan;61(1):140–148. [PubMed] [Google Scholar]
  11. Duhamel R. C., Schur P. H., Brendel K., Meezan E. pH gradient elution of human IgG1, IgG2 and IgG4 from protein A-sepharose. J Immunol Methods. 1979;31(3-4):211–217. doi: 10.1016/0022-1759(79)90133-9. [DOI] [PubMed] [Google Scholar]
  12. George J. N., Nurden A. T., Phillips D. R. Molecular defects in interactions of platelets with the vessel wall. N Engl J Med. 1984 Oct 25;311(17):1084–1098. doi: 10.1056/NEJM198410253111705. [DOI] [PubMed] [Google Scholar]
  13. Gogstad G. O., Hagen I., Krutnes M. B., Solum N. O. Dissociation of the glycoprotein IIb-IIIa complex in isolated human platelet membranes. Dependence of pH divalent cations. Biochim Biophys Acta. 1982 Jul 14;689(1):21–30. doi: 10.1016/0005-2736(82)90184-5. [DOI] [PubMed] [Google Scholar]
  14. Jennings L. K., Phillips D. R. Purification of glycoproteins IIb and III from human platelet plasma membranes and characterization of a calcium-dependent glycoprotein IIb-III complex. J Biol Chem. 1982 Sep 10;257(17):10458–10466. [PubMed] [Google Scholar]
  15. Khoory M. S., Nesheim M. E., Bowie E. J., Mann K. G. Circulating heparan sulfate proteoglycan anticoagulant from a patient with a plasma cell disorder. J Clin Invest. 1980 Mar;65(3):666–674. doi: 10.1172/JCI109712. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Kornecki E., Niewiarowski S., Morinelli T. A., Kloczewiak M. Effects of chymotrypsin and adenosine diphosphate on the exposure of fibrinogen receptors on normal human and Glanzmann's thrombasthenic platelets. J Biol Chem. 1981 Jun 10;256(11):5696–5701. [PubMed] [Google Scholar]
  17. Kunicki T. J., Pidard D., Rosa J. P., Nurden A. T. The formation of Ca++-dependent complexes of platelet membrane glycoproteins IIb and IIIa in solution as determined by crossed immunoelectrophoresis. Blood. 1981 Aug;58(2):268–278. [PubMed] [Google Scholar]
  18. Lackner H. Hemostatic abnormalities associated with dysproteinemias. Semin Hematol. 1973 Apr;10(2):125–133. [PubMed] [Google Scholar]
  19. Lackner H., Hunt V., Zucker M. B., Pearson J. Abnormal fibrin ultrastructure, polymerization, and clot retraction in multiple myeloma. Br J Haematol. 1970 Jun;18(6):625–636. doi: 10.1111/j.1365-2141.1970.tb01587.x. [DOI] [PubMed] [Google Scholar]
  20. Laemmli U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970 Aug 15;227(5259):680–685. doi: 10.1038/227680a0. [DOI] [PubMed] [Google Scholar]
  21. Lee H., Nurden A. T., Thomaidis A., Caen J. P. Relationship between fibrinogen binding and the platelet glycoprotein deficiencies in Glanzmann's thrombasthenia type I and type II. Br J Haematol. 1981 May;48(1):47–57. doi: 10.1111/j.1365-2141.1981.00047.x. [DOI] [PubMed] [Google Scholar]
  22. Levy-Toledano S., Tobelem G., Legrand C., Bredoux R., Degos L., Nurden A., Caen J. P. Acquired IgG antibody occurring in a thrombasthenic patient: its effect on human platelet function. Blood. 1978 Jun;51(6):1065–1071. [PubMed] [Google Scholar]
  23. McEver R. P., Baenziger N. L., Majerus P. W. Isolation and quantitation of the platelet membrane glycoprotein deficient in thrombasthenia using a monoclonal hybridoma antibody. J Clin Invest. 1980 Dec;66(6):1311–1318. doi: 10.1172/JCI109983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. McEver R. P., Bennett E. M., Martin M. N. Identification of two structurally and functionally distinct sites on human platelet membrane glycoprotein IIb-IIIa using monoclonal antibodies. J Biol Chem. 1983 Apr 25;258(8):5269–5275. [PubMed] [Google Scholar]
  25. Mustard J. F., Kinlough-Rathbone R. L., Packham M. A., Perry D. W., Harfenist E. J., Pai K. R. Comparison of fibrinogen association with normal and thrombasthenic platelets on exposure to ADP or chymotrypsin. Blood. 1979 Nov;54(5):987–993. [PubMed] [Google Scholar]
  26. Nachman R. L., Leung L. L. Complex formation of platelet membrane glycoproteins IIb and IIIa with fibrinogen. J Clin Invest. 1982 Feb;69(2):263–269. doi: 10.1172/JCI110448. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Nurden A. T., Caen J. P. An abnormal platelet glycoprotein pattern in three cases of Glanzmann's thrombasthenia. Br J Haematol. 1974 Oct;28(2):253–260. doi: 10.1111/j.1365-2141.1974.tb06660.x. [DOI] [PubMed] [Google Scholar]
  28. Osterland C. K., Espinoza L. R. Biological properties of myeloma proteins. Arch Intern Med. 1975 Jan;135(1):32–36. [PubMed] [Google Scholar]
  29. Palmer R. N., Rick M. E., Rick P. D., Zeller J. A., Gralnick H. R. Circulating heparan sulfate anticoagulant in a patient with a fatal bleeding disorder. N Engl J Med. 1984 Jun 28;310(26):1696–1699. doi: 10.1056/NEJM198406283102603. [DOI] [PubMed] [Google Scholar]
  30. Peerschke E. I., Zucker M. B., Grant R. A., Egan J. J., Johnson M. M. Correlation between fibrinogen binding to human platelets and platelet aggregability. Blood. 1980 May;55(5):841–847. [PubMed] [Google Scholar]
  31. Penny R., Castaldi P. A., Whitsed H. M. Inflammation and haemostasis in paraproteinaemias. Br J Haematol. 1971 Jan;20(1):35–44. doi: 10.1111/j.1365-2141.1971.tb00784.x. [DOI] [PubMed] [Google Scholar]
  32. Perkins H. A., MacKenzie M. R., Fudenberg H. H. Hemostatic defects in dysproteinemias. Blood. 1970 May;35(5):695–707. [PubMed] [Google Scholar]
  33. Phillips D. R., Agin P. P. Platelet plasma membrane glycoproteins. Evidence for the presence of nonequivalent disulfide bonds using nonreduced-reduced two-dimensional gel electrophoresis. J Biol Chem. 1977 Mar 25;252(6):2121–2126. [PubMed] [Google Scholar]
  34. Phillips D. R., Jenkins C. S., Lüscher E. F., Larrieu M. Molecular differences of exposed surface proteins on thrombasthenic platelet plasma membranes. Nature. 1975 Oct 16;257(5527):599–600. doi: 10.1038/257599a0. [DOI] [PubMed] [Google Scholar]
  35. Pidard D., Montgomery R. R., Bennett J. S., Kunicki T. J. Interaction of AP-2, a monoclonal antibody specific for the human platelet glycoprotein IIb-IIIa complex, with intact platelets. J Biol Chem. 1983 Oct 25;258(20):12582–12586. [PubMed] [Google Scholar]
  36. Ruggeri Z. M., Bader R., de Marco L. Glanzmann thrombasthenia: deficient binding of von Willebrand factor to thrombin-stimulated platelets. Proc Natl Acad Sci U S A. 1982 Oct;79(19):6038–6041. doi: 10.1073/pnas.79.19.6038. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Ruggeri Z. M., De Marco L., Gatti L., Bader R., Montgomery R. R. Platelets have more than one binding site for von Willebrand factor. J Clin Invest. 1983 Jul;72(1):1–12. doi: 10.1172/JCI110946. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Seligmann M., Brouet J. C. Antibody activity of human myeloma globulins. Semin Hematol. 1973 Apr;10(2):163–177. [PubMed] [Google Scholar]
  39. Shattil S. J., Bennett J. S. Platelets and their membranes in hemostasis: physiology and pathophysiology. Ann Intern Med. 1981 Jan;94(1):108–118. doi: 10.7326/0003-4819-94-1-108. [DOI] [PubMed] [Google Scholar]
  40. Thiagarajan P., Shapiro S. S., De Marco L. Monoclonal immunoglobulin M lambda coagulation inhibitor with phospholipid specificity. Mechanism of a lupus anticoagulant. J Clin Invest. 1980 Sep;66(3):397–405. doi: 10.1172/JCI109869. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Thiagarajan P., Shapiro S. S., Levine E., DeMarco L., Yalcin A. A monoclonal antibody to human platelet glycoprotein IIIa detects a related protein in cultured human endothelial cells. J Clin Invest. 1985 Mar;75(3):896–901. doi: 10.1172/JCI111789. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Vigliano E. M., Horowitz H. I. Bleeding syndrome in a patient with IgA myeloma: interaction of protein and connective tissue. Blood. 1967 Jun;29(6):823–836. [PubMed] [Google Scholar]
  43. Woods V. L., Jr, Oh E. H., Mason D., McMillan R. Autoantibodies against the platelet glycoprotein IIb/IIIa complex in patients with chronic ITP. Blood. 1984 Feb;63(2):368–375. [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES